Ann: Quarterly Activities and Appendix 4C Cash Flow Report, page-26

thanks actionnaire,

As a guess looks like mccusker & co are continuing to accumulate into Feb, can’t be sure, but it aligns with their ASX notice. Maybe we’ll see an increase notice this month if their accumulation run rate holds. Good to see Bell Potter becoming positive net buyers for many months in a row; they did our last cap raise, so good their clients are no longer selling. Don’t see any other instos/fund managers interested in PYC unfortunately (CEO changes/project delays are usually red flag for them)

On that note, good to see the options issued pegged at 17c given that ‘‘twas the last shareholder funding round; which gives us funding to bring VP-001 to market (~2025). I hope our next raise will be significantly higher than our last? Maybe we won’t need one?

We still have $43m in kitty; and seems to be conservatively deployed to discovery efforts; based on patent mix informing us of potential leads - we are by stealth a CNS company now given our patent mix shift/acceleration of growth towards neuro.

We’ve got a great year ahead for positive milestones to hopefully materialise.